A detailed history of Jpmorgan Chase & CO transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 38,288 shares of MORF stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,288
Previous 40,781 6.11%
Holding current value
$2.18 Million
Previous $1.44 Million 9.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$26.12 - $34.07 $65,117 - $84,936
-2,493 Reduced 6.11%
38,288 $1.3 Million
Q1 2024

May 10, 2024

SELL
$26.64 - $40.31 $521,238 - $788,705
-19,566 Reduced 32.42%
40,781 $1.44 Million
Q4 2023

Feb 12, 2024

BUY
$19.95 - $31.0 $120,717 - $187,581
6,051 Added 11.14%
60,347 $1.74 Million
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $23,740 - $66,134
1,113 Added 2.09%
54,296 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$34.33 - $62.11 $638,503 - $1.16 Million
18,599 Added 53.78%
53,183 $3.05 Million
Q1 2023

May 18, 2023

BUY
$26.01 - $48.69 $890,920 - $1.67 Million
34,253 Added 10348.34%
34,584 $1.3 Million
Q1 2023

May 11, 2023

SELL
$26.01 - $48.69 $723,598 - $1.35 Million
-27,820 Reduced 98.82%
331 $12,000
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $38,961 - $49,017
1,614 Added 6.08%
28,151 $753,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $46,927 - $70,444
2,111 Added 8.64%
26,537 $751,000
Q2 2022

Aug 11, 2022

BUY
$19.74 - $43.01 $80,499 - $175,394
4,078 Added 20.04%
24,426 $531,000
Q1 2022

May 11, 2022

BUY
$36.25 - $52.02 $138,656 - $198,976
3,825 Added 23.15%
20,348 $816,000
Q4 2021

Feb 10, 2022

SELL
$43.27 - $65.72 $499,076 - $758,014
-11,534 Reduced 41.11%
16,523 $783,000
Q3 2021

Nov 12, 2021

BUY
$53.61 - $67.5 $1.5 Million - $1.89 Million
28,057 New
28,057 $1.59 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.